Find in Library

Novel antifungal drugs are urgently needed to treat candidiasis caused by the emerging fungal multidrug-resistant pathogen <i>Candida auris</i>. In this study, the most cost-effective drug repurposing technology was adopted to identify an appropriate option among the 1615 clinically approved drugs with anti-<i>C. auris</i> activity. High-throughput virtual screening of 1,3-beta-glucanosyltransferase inhibitors was conducted, followed by an analysis of the stability of 1,3-beta-glucanosyltransferase drug complexes and 1,3-beta-glucanosyltransferase–dutasteride metabolite interactions and the confirmation of their activity in biofilm formation and planktonic growth. The analysis identified dutasteride, a drug with no prior antifungal indications, as a potential medication for anti-<i>auris</i> activity in seven clinical <i>C. auris</i> isolates from Saudi Arabian patients. Dutasteride was effective at inhibiting biofilm formation by <i>C. auris</i> while also causing a significant reduction in planktonic growth. Dutasteride treatment resulted in disruption of the cell membrane, the lysis of cells, and crushed surfaces on <i>C. auris</i>, and significant (<i>p</i>-value = 0.0057) shrinkage in the length of <i>C. auris</i> was noted at 100,000×. In conclusion, the use of repurposed dutasteride with anti-<i>C</i>. <i>auris</i> potential can enable rapid recovery in patients with difficult-to-treat candidiasis caused by <i>C. auris</i> and reduce the transmission of nosocomial infection.